Catalyst MSK 002: A Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

July 26, 2018
https://clinicaltrials.gov/ct2/show/NCT03304054
Myasthenia Gravis
Principal Investigator: Kavita M Grover, MD
Myasthenia Gravis, MG, MuSK positive, AChR antibody positive
Accepting Participants